US 11,865,163 B2
Methods and materials for using butyrylcholinesterases to treat cancer
William S. Brimijoin, Rochester, MN (US); Liewei Wang, Rochester, MN (US); Yang Gao, Rochester, MN (US); Ping Chen, Rochester, MN (US); Liyi Geng, Rochester, MN (US); Jia Yu, Rochester, MN (US); Judy C. Boughey, Rochester, MN (US); and Matthew P. Goetz, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 16/333,835
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Sep. 15, 2017, PCT No. PCT/US2017/051694
§ 371(c)(1), (2) Date Mar. 15, 2019,
PCT Pub. No. WO2018/053216, PCT Pub. Date Mar. 22, 2018.
Claims priority of provisional application 62/394,939, filed on Sep. 15, 2016.
Prior Publication US 2019/0255154 A1, Aug. 22, 2019
Int. Cl. A61K 38/46 (2006.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01); C12N 9/18 (2006.01)
CPC A61K 38/465 (2013.01) [A61P 35/00 (2018.01); C12N 9/18 (2013.01); C12N 15/86 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); C12N 2710/10043 (2013.01); C12N 2750/14143 (2013.01); C12Y 301/01008 (2013.01)] 11 Claims
 
1. A method for treating triple negative breast cancer within a mammal, wherein said method comprises administering a butyrylcholinesterase (BChE) polypeptide or a nucleic acid encoding said polypeptide to said mammal, wherein the number of cancer cells within said mammal is reduced or the growth rate of said cancer within said mammal is reduced, and wherein said BChE polypeptide is not modified by fusion to another polypeptide.